Lupin Healthcare are committed to supporting the NHS in its goal of becoming net zero by 20401
Through carbon offsetting, Lupin Healthcare’s pMDIs portfolio has been certified as carbon neutral by Carbon Footprint Ltd.2-5
Every inhaler, including Dry Powder Inhalers (DPIs) has a carbon footprint associated with its production, and use6
Lupin Healthcare commissioned Carbon Footprint Ltd to complete Life Cycle Assessments (LCA) to understand the greenhouse gas (GHG) emissions associated with its pMDI portfolio.
This assessment follows the principles of the Greenhouse Gas Protocol and ISO 14067:2018, and focus on the embodied GHG emissions of raw materials, the transport of these materials, the manufacture/processing, distribution, use and disposal of
Luforbec and Beclu pMDIs.2,3
By understanding the GHG emissions associated with the various stages of Luforbec’s life cycle, we can take steps to reduce these.
We offset the carbon footprint of all Lupin Healthcare pMDIs sold in the UK through supporting global sustainability and environmental projects. Through this process Luforbec and Beclu pMDIs have been certified as carbon neutral products by Carbon Footprint Ltd.2-5
For more information on the Carbon Footprint Standard requirements and methodology click here.
References: 1. NHS Delivering Net Zero Health Service https://www.england.nhs.uk/greenernhs/a-net-zero-nhs/ Accessed April 2023. 2. Carbon Footprint Limited, Luforbec Carbon Assessment Report 2022. Data on File. 3. Carbon Footprint Limited, Beclu Carbon Assessment Report 2023. Data on File. 4. Certifications of carbon neutrality for Luforbec 100/6 & 200/6 pMDI. 5. Certifications of carbon neutrality for Beclu 100 & 200 pMDI. 6. MIMS: Inhaler Carbon Emissions. https://www.mims.co.uk/inhaler-carbon-emissions/respiratory-system/article/1739635. Accessed: April 2023.
UK-LUP-2208-00003 DOP: September 2022